Images List Premium Download Classic

Receptor

Receptor-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Detection device, detection method, and non-transitory computer-readable recording medium storing detection program
Panasonic Intellectual Property Management Co., Ltd.
October 12, 2017 - N°20170293812

A detection device includes: a light source that emits, toward an object, light of a first wavelength band, and light of a second wavelength band that is less readily absorbed by water than the light of the first wavelength band; a polarization splitter that splits at least one of s-polarized light and p-polarized light from light that has been reflected ...
Developer cartridge
Apex Technology Co., Ltd.
October 12, 2017 - N°20170293254

A developer cartridge is provided, which includes a toner cartridge, a developer stifling device located in the toner cartridge, a supply roller for supplying a developer to a developer roller, a developer roller for developing an electrostatic latent image on a photoconductor, and a power receptor for driving only one of gear sets of the above means to receive a ...
Genetically encoded calcium indicators and methods of use
Howard Hughes Medical Institute
October 12, 2017 - N°20170292943

Genetically encoded calcium indicator (geci) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of g-protein coupled receptor (gpcr) or ion channels and methods of monitoring neural activity also are provided.
Receptor Patent Pack
Download 2409+ patent application PDFs
Receptor Patent Applications
Download 2409+ Receptor-related PDFs
For professional research & prior art discovery
inventor
  • 2409+ full patent PDF documents of Receptor-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method for modulating car-induced immune cells activity
Cellectis
October 12, 2017 - N°20170292118

The present invention relates to a method to modulate the level of activation of an engineered immune cell (such as a chimeric antigen receptor t-cell) for immunotherapy. The present invention also relates to cells obtained by the present method, preferably comprising said modulable/tunable chimeric antigen receptors for use in therapeutic or prophylactic treatment.
Bispecific her2 antibodies
Medlmmune, Llc
October 12, 2017 - N°20170291955

The present invention relates to anti-her2 binding molecules (e. G., antibodies and antigen binding fragments thereof), derived her2-binding molecules (e. G., bispecific anti-her2 antibodies), and antibody-drug conjugates (adc) that bind the extracellular domain of the her2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with her2-mediated signal transduction.
Glypican-3 antibody and uses thereof
The Trustees Of The University Of Pennsylvania
October 12, 2017 - N°20170291954

The present invention relates to compositions and methods of isolated polynucleotides that encode or polypeptides comprising glypican-3 (gpc3). The invention also includes a chimeric antigen receptor (car) wherein the car is able to target gpc3. The invention further includes methods of treating a subject or diagnosing and treating diseases, disorders or conditions associated with dysregulated glypican-3.
Receptor Patent Pack
Download 2409+ patent application PDFs
Receptor Patent Applications
Download 2409+ Receptor-related PDFs
For professional research & prior art discovery
inventor
  • 2409+ full patent PDF documents of Receptor-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method for treating multiloculated hydrocephalus by administering an anti-il6 receptor antibody
Imam Abdulrahman Bin Faisal University
October 12, 2017 - N°20170291950

The invention is directed to a method of treating multiloculated hydrocephalus comprising administering to a subject who is suffering from multiloculated hydrocephalus an antibody that binds to an il-6 receptor.
Anti-interferon gamma antibodies and methods of use thereof
Novimmune Sa
October 12, 2017 - N°20170291943

The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hifnγ), thereby modulating the interaction between ifnγ and its receptor, ifnγ-r, and/or modulating the biological activities of ifnγ. The invention also relates to the use of such anti-ifnγ antibodies in the prevention ...
Treatment of depression using agents that block binding of il-6 to il-6 receptor
Janssen Biotech, Inc.
October 12, 2017 - N°20170291942

A method for treating depression or fatigue in a subject comprises administering an agent that blocks binding of il-6 to il-6 receptor, for example, an anti-il-6 antibody or an antigen-binding fragment thereof that may comprise a heavy chain variable region and a light chain variable region of seq id no:99 and seq id no:97, respectively or a heavy chain variable ...
Bmprii polypeptides and uses thereof
Acceleron Pharma, Inc.
October 12, 2017 - N°20170291933

In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of bone morphogenetic protein receptor type ii (bmprii) polypeptide binds to ligands including bmp10, bmp15, activin b and bmp9 and may be used to treat fibrotic and angiogenic disorders.
Delta receptor agonist peptides and use thereof
Ariel Scientific Innovations Ltd.
October 12, 2017 - N°20170291922

Peptides effective as delta opioid receptor agonists and compositions comprising same are provided. Further provided are methods for targeting medical conditions amenable to treatment with an opioid receptor agonist, including but not limited to, conditions involving pain as well as reducing cocaine craving.
Therapeutic compounds as inhibitors of the orexin-1 receptor
C4x Discovery Limited
October 12, 2017 - N°20170291897

The present invention relates to compounds that are inhibitors of the orexin-1 receptor. The compounds have the structural formula i defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.
1,2,4-triazine-4-amine derivatives
Heptares Therapeutics Limited
October 12, 2017 - N°20170291888

According to the invention there is provided a compound of formula a1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the a1-a21, or, particularly, the a2, receptor wherein the compound of formula a1 has the structure, wherein, a represents cy1 or heta; cy1 represents a 5- to 14-membered aromatic, fully ...
Receptor Patent Pack
Download 2409+ patent application PDFs
Receptor Patent Applications
Download 2409+ Receptor-related PDFs
For professional research & prior art discovery
inventor
  • 2409+ full patent PDF documents of Receptor-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Activation of adaptive immune processes for the treatment of cancers and infectious diseases
Susavion Biosciences, Inc.
October 12, 2017 - N°20170290922

Polypeptides, such as a multi-valent polypeptide designated svd2, useful in pharmaceutical compositions for stimulation of the adaptive arm of the immune system. Svd2 demonstrated in vivo activity in a syngeneic mouse model. Svd2 is biologically active at nanomolar concentrations. These properties are believed to result as a consequence of the ability of svd2 to cross-link cell-surface receptors.
Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
Dana-farber Cancer Institute, Inc.
October 12, 2017 - N°20170290911

The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor ccr4. This antibody is derived from ccr4-igg1 and recognizes the same epitope. This antibody contains either an igg4 or a stabilized igg4 in order to improve binding efficiency and reduce in vivo fab arm exchange. Binding of the antibodies ...
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
Purdue Research Foundation
October 12, 2017 - N°20170290900

Cytotoxic lymphocytes expressing chimeric antigen receptors (car) that target and bind small conjugate molecules (scm) are disclosed, as well as methods of using the cells and the scms in the treatment of cancer.
Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against ...
Immatics Biotechnologies Gmbh
October 12, 2017 - N°20170290897

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated t-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor ...
Compositions and methods for treating inflammatory conditions of the ocular surface
The Schepens Eye Research Institute, Inc.
October 12, 2017 - N°20170290888

This application discloses ophthalmic formulations and methods for treating inflammatory disease and conditions of the ocular surface with one or more c-c chemokine receptor type 7 (ccr7) antagonists. The compositions may be formulated for subconjunctival or topical administration to the eye and are effective in the treatment of inflammatory disease and conditions of the ocular surface.
Vascular disruption agents and uses thereof
Genentech, Inc.
October 12, 2017 - N°20170290883

Uses of apo2l/trail polypeptides and death receptor agonist antibodies to disrupt tumor associated vasculature are provided. Methods of treating cancer in mammals, kits, and articles of manufacture are also provided.
Methods of treating cancer with tubulysin conjugates
Endocyte, Inc.
October 12, 2017 - N°20170290878

The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating folate receptor-expressing cancers with a folate-tubulysin conjugate. The invention described herein also relates to methods of treating folate-expressing cancers with a folate tubulysin conjugate in patients where stable disease results after treatment with the folate-tubulysin conjugate.
Compositions and methods for long acting proteins
Novartis Ag
October 12, 2017 - N°20170290876

The present invention is based, in part, on the discovery of peptide tags that increase the half-life and/or mean residence time of proteins or nucleic acids in the eye. In certain aspects the invention peptide tags increase the half-life and/or mean residence time of antibodies and antigen binding fragments, therapeutic proteins, protein receptors, darpins and/or aptamers in ...
Loading